This announcement is not an offer to sell, or a solicitation of an offer to acquire any securities. This announcement is not a prospectus and investors should not purchase any securities referred to in this announcement except on the basis of information in the prospectus published by Probiodrug AG as approved by the competent German regulator Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) on 10 October 2014 and passported to the Dutch Authority for Financial Markets (Autoriteit Financiële Markten) in connection with the Initial Public Offering and admission to trading of its shares on Euronext Amsterdam.
Probiodrug announces the exercise of the Greenshoe Option, increasing the gross proceeds of the Offer to EUR 23.2 million
HALLE/SAALE, Germany, November 12, 2014 – Probiodrug AG announces that, in connection with its initial public offering on the regulated market of Euronext Amsterdam, the Greenshoe Option granted to Kempen & Co, in their role as Sole Global Coordinators and Bookrunners (acting on behalf of the Underwriters as Stabilization Manager), has been exercised today by Kempen & Co and the Management Board of Probiodrug AG has resolved upon the issuance of 48,796 New Shares from authorized capital today. This number of shares equals the number of shares that have been over-allotted in the initial public offering. Based on the Offer Price of €15.25 per share this will result in additional gross proceeds of EUR 744,139.00 and the total gross proceeds of the Offer of EUR 23,244,126.25 (total net proceeds of approx. EUR 21 million). As a result, the total number of Ordinary Shares issued and placed by Probiodrug in connection with its IPO amount to 1,524,205 new Ordinary Shares. The total number of shares of Probiodrug following the registration of the capital increase in connection with the execution of the Greenshoe Option, which is expected to occur on 14 November 2014, will be 6,765,898.
Kempen & Co, acting as stabilisation manager on behalf of the Underwriters, has informed us that no stabilisation measures have been taken in connection with the initial public offering of the shares in Probiodrug AG (ISIN: DE0007921835, WKN: 792183), whose trading at Euronext Amsterdam commenced on 27 October 2014. The stabilisation period had begun on 27 October 2014 and was ended on 12 November 2014. The Greenshoe option which had been granted by Probiodrug has been exercised today and the remaining Greenshoe Option for further New Shares has been waived. The stabilization period was terminated accordingly.
For more information please contact:
|Dr Konrad Glund, CEO, Probiodrug||Hume Brophy|
|Email: firstname.lastname@example.org||Email: email@example.com|
|Tel: +44 (203) 440-5653|
Registered at Amtsgericht of Stendal, HRB 213719
Management Board: Dr. Konrad Glund, Dr. Hendrik Liebers, Dr. Inge Lues
Chairperson of the Supervisory Board: Dr. Erich Platzer
About Probiodrug AG
Headquartered in Halle, Germany, Probiodrug AG (Euronext: PBD) is a biopharmaceutical company focused on the development of new therapeutic products for the treatment of Alzheimer’s Disease.
Alzheimer’s Disease is a neurological disorder, which is the most common form of dementia. Probiodrug has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight Alzheimer’s Disease. The Company has medical use and composition of matter patents related to the inhibition of Glutaminyl Cyclase (QC) and anti-pGlu-Abeta- specific monoclonal antibodies, providing it, in the Company’s view, with a leading position in this field of research.
These materials are not for distribution, directly or indirectly, in or into the United States (including its territories and dependencies, any State of the United States and the District of Columbia). These materials do not constitute or form a part of any offer or solicitation to purchase or subscribe for securities. The shares in Probiodrug AG (the “Shares”) mentioned herein may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”). The Shares have not been, and will not be, registered under the Securities Act and will not be offered or sold in the United States, except on the basis of applicable exemptions from registration. There will be no public offering of securities in the United States or anywhere outside of The Netherlands. The public offer in The Netherlands was made exclusively by means of and on the basis of an English-language prospectus.